Advances in development of antiviral strategies against respiratory syncytial virus.
10.1016/j.apsb.2025.02.015
- Author:
Ge YANG
1
;
Guangyu JIANG
1
;
Jiandong JIANG
1
;
Yuhuan LI
1
Author Information
1. State Key Laboratory of Bioactive Substances and Functions of Natural Medicines, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China.
- Publication Type:Review
- Keywords:
Antivirals;
Drug development;
Infection;
New strategies;
Respiratory syncytial virus (RSV);
Therapeutic targets;
Viral entry;
Viral replication
- From:
Acta Pharmaceutica Sinica B
2025;15(4):1752-1772
- CountryChina
- Language:English
-
Abstract:
Human respiratory syncytial virus (RSV) is a major cause of lower respiratory tract infections in infants and young children, as well as an important cause of respiratory tract infections in immunocompromised patients and the elderly, which poses a significant economic and social burden worldwide. In recent years, substantial progress has been made in understanding the structure and function of RSV proteins and the interactions between RSV with host factors which is helpful to the discovery of new therapeutic targets and the development of novel interventions. Although two vaccines and two monoclonal antibodies for RSV prevention have been approved, the antiviral treatment remains an unmet clinical need. In this review, we summarize the structure, protein functional properties, and pathological mechanisms of RSV and the current status of RSV drug development. In addition, remaining challenges and innovative ideas for RSV prevention and treatment have also been highlighted.
